Prostate Specific Antigen (PSA), Total

Prostate-Specific Antigen (PSA) is a protein produced by cells in the prostate gland. Small amounts of PSA naturally leak into the bloodstream, which is why it can be measured through a simple blood test. PSA levels tend to rise slowly with age because the prostate gradually enlarges over time, even in healthy men.

PSA becomes clinically important because prostate conditions—both benign and cancerous—can increase the amount of PSA that enters the bloodstream. This is why PSA is used as a screening and monitoring tool. However, PSA is not cancer-specific. Levels can rise from benign prostate enlargement, inflammation, infection, and urinary retention for example.

Prostate specific antigen is measured in three forms:

1. Total PSA – the overall amount of PSA in the blood, including both free (unbound) and protein-bound forms.

2. Free PSA – the fraction of PSA that circulates freely, not attached to other proteins.

3. % Free PSA – the ratio of free PSA to total PSA, expressed as a percentage.

Total PSA is used for initial prostate cancer screening, while Free PSA and % Free PSA help distinguish between benign conditions (like enlargement or inflammation) and malignant disease.

Understanding PSA is important because it helps identify prostate cancer early—often before symptoms appear—when treatment outcomes are most favorable. Prostate cancer is one of the most common cancers in men, and early detection can significantly reduce the risk of dying from the disease. PSA testing is most useful for men between 50 and 69 years, where screening has shown the greatest benefit.

However, PSA is a sensitive but not specific marker, meaning it can detect changes in the prostate but cannot determine the cause on its own. Elevated PSA does not always mean cancer. In many cases, a high PSA level is caused by benign enlargement (a very common age-related change), inflammation, or temporary factors such as ejaculation or infection.

Total PSA is the primary screening marker. Elevated levels can occur in prostate cancer, but also in benign prostatic hyperplasia (BPH), prostatitis, or after sexual activity, cycling, or medical procedures.

Free PSA helps refine interpretation. Men with prostate cancer tend to have lower free PSA because more PSA binds to proteins in cancerous tissue.

% Free PSA provides the clearest distinction in the “grey zone” (total PSA 4–10 ng/mL).

• A low % Free PSA (<25%) indicates a higher probability of prostate cancer.

• A high % Free PSA (>25%) is more consistent with benign conditions like BPH.
  

Used together, these markers reduce unnecessary biopsies while maintaining high sensitivity for detecting clinically significant prostate cancers.

Screening recommendations

According to Cancer Council Australia and international guidelines:

• Men aged 50–69 years: Should discuss PSA screening (Total, Free, and % Free) with their healthcare provider to weigh benefits and risks.

• High-risk men (family history or African descent): May start screening at age 45.

• Very high-risk men (multiple first-degree relatives diagnosed before age 65): May start at age 40.

Total PSA (ng/mL)

Rescreen interval

<1.0ng/mL : Every 2–4 years

1.0–3.0ng/mL: Every 1–2 years

>3.0ng/mL: Further evaluation with Free and % Free PSA

If Total PSA is between 3.0–5.5 ng/mL and % Free PSA <25%, biopsy or imaging is typically advised.

Several non-cancerous factors can temporarily alter PSA results:

• Benign prostatic hyperplasia (BPH): Naturally increases PSA production.

• Inflammation or infection (prostatitis): Can cause transient elevations.

• Ejaculation or vigorous exercise (e.g., cycling): May raise PSA for 24–48 hours.

• Recent urological procedures: Catheterisation or biopsy temporarily elevate PSA.

• Medications: Finasteride and other prostate drugs can lower PSA readings.

• Age and prostate size: PSA levels tend to rise gradually with age and gland volume.

For ongoing prostate health:

• Maintain a healthy weight and reduce visceral fat — metabolic inflammation impacts prostate biology.

• Eat a Mediterranean-style diet rich in lycopene (tomatoes), cruciferous vegetables (broccoli, kale), omega-3 fats (salmon, sardines), and green tea polyphenols.

• Limit alcohol and processed meats, which can increase inflammatory stress.

• Support hormonal balance with regular exercise, adequate sleep, and stress management.

For elevated results:

Discuss next steps with your clinician. This may include repeat testing, imaging (e.g., MRI), or biopsy depending on the magnitude of elevation.

1. Wei, J. T., Barocas, D., Carlsson, S., et al. (2023). Early detection of prostate cancer: AUA/SUO guideline part I: Prostate cancer screening. The Journal of Urology, 210(1), 46–53. https://doi.org/10.1097/JU.0000000000003491

2. Raychaudhuri, R., Lin, D. W., & Montgomery, R. B. (2025). Prostate cancer: A review. JAMA, 333(16), 1433–1446. https://doi.org/10.1001/jama.2025.0228

3. Sandhu, S., Moore, C. M., Chiong, E., et al. (2021). Prostate cancer. Lancet, 398(10305), 1075–1090. https://doi.org/10.1016/S0140-6736(21)00950-8

4. Yim, K., Ma, C., Carlsson, S., et al. (2023). Free PSA and clinically significant and fatal prostate cancer in the PLCO screening trial. The Journal of Urology, 210(4), 630–638. https://doi.org/10.1097/JU.0000000000003603

5. Pinsky, P. F., & Parnes, H. (2023). Screening for prostate cancer. The New England Journal of Medicine, 388(15), 1405–1414. https://doi.org/10.1056/NEJMcp2209151